Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:164692.
doi: 10.1155/2014/164692. Epub 2014 Jul 23.

Sustained-release corticosteroid options

Mariana Cabrera  1 , Steven Yeh  2 , Thomas A Albini  1
Affiliations
Review

Sustained-release corticosteroid options

Mariana Cabrera et al. J Ophthalmol. 2014.

Abstract

Sustained-release corticosteroid treatment has shown to be a promising strategy for macular edema due to retinovascular disease (i.e., diabetes and retinal vein occlusion) and for the treatment of noninfectious posterior uveitis. Clinicians now have the option of three sustained-release corticosteroid implants: Ozurdex (Allergan Inc., Irvine, CA) which releases dexamethasone and two devices that release fluocinolone acetonide, Retisert (Bausch & Lomb, Rochester, NY), and Iluvien (Alimera Science, Alpharetta, GA). Each has different physical characteristics and duration effect and has been approved for different indications. Herein we provide a summary of the current clinical knowledge regarding these implants.

PubMed Disclaimer

References

    1. Schwartz SG, Flynn HW, Jr., Scott IU. Intravitreal corticosteroids in the management of diabetic macular edema. Current Ophthalmology Reports. 2013;1(3):144–149. - PMC - PubMed
    1. de Smet MD. Corticosteroid intravitreal implants. Developments in Ophthalmology. 2012;51:122–133. - PubMed
    1. Glacet-Bernard A, Coscas G, Zourdani A, Soubrane G, Souied EH. Steroids and macular edema from retinal vein occlusion. European Journal of Ophthalmology. 2011;21(supplement 6):S37–S44. - PubMed
    1. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916.e1–1916.e7. - PubMed
    1. Chang-Lin J, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Investigative Ophthalmology and Visual Science. 2011;52(1):80–86. - PubMed

LinkOut - more resources